Skip to main content
. 2023 Sep 14;13(10):2180–2191. doi: 10.1158/2159-8290.CD-22-1340

Table 1.

Clinical–pathologic characteristics of the cohorts

Cohort Classifier Subtype N %
Healthy Age 34.2 years (28–40) 12 100%
Milk stagea Colostrum 0 0%
Transitional 0 0%
Mature 12 100%
Breast cancer cases Age 36.2 years (25–48) 19 100%
pT 1 5 26%
2 8 42%
3 5 26%
4 1 5%
pN 0 9 47%
≥1 10 53%
M 0 18 95%
1 1 5%
Stage I 2 11%
II 11 58%
III 5 26%
IV 1 5%
HR Positive 16 84%
Negative 3 16%
HER2 Positive 1 5%
Negative 18 95%
Molecular subtypeb Luminal A 6 32%
Luminal B 9 47%
HER2+ 1 5%
TNBC 3 16%
Diagnosis timec PrBC 10 53%
PPBC 9 47%
Histologic subtype IDC 15 79%
ILC 4 21%
Milk stagea Colostrum 3 21%
Transitional 1 7%
Mature 11 79%

NOTE: Healthy and breast cancer–diagnosed individuals are described in detail.

Abbreviations: HR, hormone receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; PR, progesterone receptor; TNBC, triple-negative breast cancer.

aMilk stage is defined as colostrum: 0–5 days after childbirth; transitional: 6–14 days after childbirth; and mature: after 14 days from childbirth.

bMolecular subtype is based on IHC: luminal A is defined as ER- or PR-positive, HER2-negative, and Ki-67 <20%; luminal B is defined as ER- or PR-positive, HER2-negative, and Ki-67 ≥20%; and HER2+ is defined as HER2-positive regardless of ER, PR, and Ki-67 status. TNBC is defined as ER-, PR-, and HER2-negative.

cDiagnosis time refers to breast cancer diagnosed during pregnancy (PrBC) or postpartum (PPBC).